US Stock MarketDetailed Quotes
ELTX Elicio Therapeutics
- 4.260
- +0.100+2.40%
Close Oct 31 16:00 ET
- 4.260
- 0.0000.00%
Post 16:04 ET
45.90MMarket Cap-1130P/E (TTM)
4.790High4.230Low21.17KVolume4.250Open4.160Pre Close93.54KTurnover0.25%Turnover RatioLossP/E (Static)10.77MShares11.45052wk High-27.84P/B35.98MFloat Cap2.96052wk Low--Dividend TTM8.44MShs Float263.000Historical High--Div YieldTTM13.46%Amplitude2.960Historical Low4.419Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Elicio Therapeutics Stock Forum
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
Elicio Therapeutics (Nasdaq: ELTX) announced two upcoming presentations in November 2024. At the SITC 39th Annual Meeting (Nov 6-10), they will present updated T cell and Disease-Free Survival data from the AMPLIFY-7P Phase 1 trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumor...
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
Elicio Therapeutics (Nasdaq: ELTX)announced three upcoming presentations focusing on its lymph node targeted, mKRAS-specific Amphiphile vaccines. The presentations will take place at:
1. AACR Special Conference (Sept 15-18, 2024, Boston): Dr. Eileen O'Reilly will present Phase I AMPLIFY-7P trial updates.
2. RAS-Targeted Drug Developm...
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
NEWS
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics revealed preliminary data from their AMPLIFY-7P Phase 1a study of ELI-002 7P at the ASCO 2024 Annual Meeting. The cancer vaccine candidate, targeting mKRAS-driven solid tumors, showed promising results. ELI-002 7P was well tolerated and induced a significant (~100x...
No comment yet